Fate Therapeutics shares are trading lower. The company presented clinical data this weekend featuring its off-the-shelf CAR T-cell program FT836 at ASCO Annual Meeting.

Benzinga Newsdesk www.benzinga.com Neutral 65.7%

Neg 0% Neu 65.7% Pos 0%

Comments

No comments yet. Be the first!